CoChat

mGluR5 Antagonists 2-Methyl-6-(phenylethynyl)-pyridine and (E)-2-Methyl-6-(2-phenylethenyl)-pyridine Reduce Traumatic Neuronal Injury In Vitro and In Vivo by AntagonizingN-Methyl-d-aspartate Receptors

Movsesyan, Vilen A., O'Leary, Deirdre M., Fan, Lei, Bao, Weili, Mullins, Paul G.M., Knoblach, Susan M., Faden, Alan I. · 2001 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 121

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The effect of selective group I metabotropic glutamate receptor subtype 5 (mGluR5) antagonists 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and (E)-2-methyl-6-(2-phenylethenyl)-pyridine (SIB-1893) on neuronal cell survival and post-traumatic recovery was examined using rat in vitro and in vivo trauma models. Treatment with MPEP and SIB-1893 showed significant neuroprotective effects in rat cortical neuronal cultures subjected to mechanical injury. Application of the antagonists also attenuated glutamate- and N-methyl-D-aspartate (NMDA)-induced neuronal cell death in vitro. Intracerebroventricular administration of MPEP to rats markedly improved motor recovery and reduced deficits of spatial learning after lateral fluid percussion-induced traumatic brain injury. Lesion volumes as assessed by magnetic resonance imaging were also substantially reduced by MPEP treatment. Although we show that MPEP acts as a potent mGluR5 antagonist in our culture system, where it completely blocks agonist-induced phosphoinositide hydrolysis, electrophysiological and pharmacological studies indicate that MPEP and SIB-1893 also inhibit NMDA receptor activity at higher concentrations that are neuroprotective. Taken together, these data suggest that MPEP and SIB-1893 may have therapeutic potential in brain injury, although the mechanisms of neuroprotective action for these drugs may reflect their ability to modulate NMDA receptor activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(24)29660-9

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 121

Metadata

Authors
Movsesyan, V. A., O'Leary, D. M., Fan, L., Bao, W., Mullins, P. G. M., Knoblach, S. M., & Faden, A. I.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2001-01
Volume
296
Issue
1
Pages
41-47
ISSN
0022-3565 (ISSN-L)
OpenAlex
W1923206427
Cited by
121
References
3
FWCI
8.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mGluR5 Antagonists 2-Methyl-6-(phenylethynyl)-pyridine and (E)-2-Methyl-6-(2-phenylethenyl)-pyridine Reduce Traumatic Neuronal Injury In Vitro and In Vivo by AntagonizingN-Methyl-d-aspartate Receptors. https://app.cochat.ai/papers/10.1016/s0022-3565(24)29660-9
The paper
Movsesyan, V. A., O'Leary, D. M., Fan, L., Bao, W., Mullins, P. G. M., Knoblach, S. M., & Faden, A. I. (2001). mGluR5 Antagonists 2-Methyl-6-(phenylethynyl)-pyridine and (E)-2-Methyl-6-(2-phenylethenyl)-pyridine Reduce Traumatic Neuronal Injury In Vitro and In Vivo by AntagonizingN-Methyl-d-aspartate Receptors. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)29660-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.